Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381879 | 0.88 | ALDH1A1 (0.42) | SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL13381979 | 0.87 | ALDH1A1 (0.38) | TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13381974 | 0.85 | RXRA (0.37) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13382018 | 0.84 | NPC1 (0.32) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13381962 | 0.84 | TDP1 (0.39) | MEN1KMT2A | |
| SCHEMBL13381972 | 0.84 | MAOB (0.39) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13381964 | 0.84 | KMT2A (0.45) | SMN1; SMN2P2RX3MEN1KMT2A | |
| SCHEMBL13382094 | 0.83 | ALOX5 (0.39) | TSHR | |
| SCHEMBL13381995 | 0.83 | POLB (0.41) | SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL13381987 | 0.83 | RAB9A (0.43) | SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | TSHR 65/4885SMN1; SMN2 3564/4885P2RX3 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.